| Acquired by | Sanofi Aventis |
| Price | $500M |
| Date | 4/09 |
| Website | biparsciences.com |
| Category | BioTech |
| Phone | (650) 635-6050 |
| Employees | |
| Founded | 2002 |
| Description | PARP Inhibitors (Cancer Therapeutics) |
BiPar Sciences Inc. is a Brisbane, CA based developer of PARP inhibitors as cancer therapies. BiPar’s key experimental product is BSI-201, currently in mid-stage trials for advanced breast cancer, ovarian cancer and other tumors.
BiPar has raised around $60 million in VC funding, from firms like Domain Associates, Canaan Partners, Vulcan Capital, PolyTechnos Venture-Partners, Asset Management Company and Quantum Technology Partners. It also has raised venture debt from Lighthouse Capital Partners.
On April 15th, 2009, French drug maker Sanofi-Aventis S.A. announced it was acquiring BiPar Sciences for up to $500 million.
BSI-201, targets PARP, or poly (ADP-ribose) polymerase, a key enzyme involved in DNA repair and cell proliferation. By inhibiting the enzymatic activity of PARP, BSI-201 significantly enhances the anti-tumor effects of chemotherapy and has shown promising safety and efficacy results in patients with solid tumors.
BSI-201 is in Phase 2 clinical studies of patients with triple negative breast cancer, ovarian cancer and other malignancies.
